HMG-HCG therapy in patients with hypergonadotropic ovarian anovulation: one pregnancy case report and ovulation and pregnancy rate.
The aim of this study is to advocate the delivery of human menopausal gonadotropin (HMG) and human chorionic gonadotropin (HCG) therapy to patients with hypergonadotropic ovarian anovulation (Hyper-OA). HMG-HCG therapy was carried out in six patients (16 cycles) with Hyper-OA and nine patients (26 cycles) with hypogonadotropic pituitary anovulation (Hypo-PA) as controls. In this study, two patients with Hyper-OA ovulated after HMG-HCG therapy, and one of them conceived in the next cycle of the therapy. This patient is presented in detail as a case report. The ovulation rate in Hyper-OA proved to be 33.3% of patients and 12.5% of cycles as compared with 100% of patients with Hypo-PA and 65.3% of their cycles. These results suggest that although ovulation and pregnancy rate are very low, it is worth trying HMG-HCG therapy in patients with Hyper-OA, at least for one or two cycles.
D000328:Adult; D000858:Anovulation / Q000188:drug therapy*; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000627:therapeutic use*; D010060:Ovulation; D011247:Pregnancy; D011374:Progesterone / Q000097:blood
D006063:Chorionic Gonadotropin; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone